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Exhaled Breath Nitric Oxide: 
Is There A Baseline Difference Due To Ethnicity? 
 
Sunita I. Patel, M.D. 
ABSTRACT 
  
The air that humans exhale contains various chemical markers whose levels have 
been associated with various respiratory disorders.  Therefore, measurement of these 
markers offers a potential method of examining airway disease status.  Furthermore, 
exhaled breath offers the advantage of being easy to collect and non-invasive. Hence, 
these exhaled breath markers are potentially of significant clinical use in examining 
airways.  Therefore, examination of exhaled breath has become the subject of intense 
study.  Current research is targeting the development of methods and parameters for 
looking at these markers. 
The goal of this cross-sectional pilot study was to consider the variability in the 
measurement of these exhaled breath markers between members of different ethnic 
populations.  Specifically, measurements of the exhaled breath marker Nitric Oxide (NO) 
were compared between two ethnic groups (Caucasian men versus men of African 
descent). Ten healthy men in each group were studied to examine whether baseline NO 
measurements differed between them.   
 vi 
In this study, a cross-sectional design was used.  The study sample consisted of 
young, healthy men with no history of environmental allergies, asthma, or lung diseases 
and no significant smoking history.  A total of twenty-five men volunteered for the study, 
including fourteen men of Caucasian descent and eleven men of African descent.  
Because four men were excluded and one withdrew, ten men in each ethnic group were 
included in the final analysis.  
The source population from which the sample was drawn included students and 
workers.  All participants were residing in Florida at the time of study.  Ideally, the target 
population for this study was young, healthy, working men. 
Large inter-measurement variation was seen between the participants of each 
ethnic group.  This was hypothesized to be attributed to a tri-modal distribution due to the 
existence of 3 populations of subjects:  (1) asymptomatic with normal airways, where NO 
levels were under 30 parts per billion (ppb); (2) asymptomatic with airway pathology, 
where NO levels were over 30 ppb; and (3) asymptomatic just before the onset of an 
upper respiratory tract infection, where NO levels were over 60 ppb.   
This pilot study did not find statistically significant evidence that there is a 
difference in the baseline exhaled breath NO measurements between the two ethnic 
groups studied.  Nonetheless, in participants with NO levels under 30 ppb the mean of the 
African group was found to be 7.6 ppb lower than the mean of the Caucasian group when 
attempts were made to exclude individuals with underlying airway pathology or 
imminent upper respiratory tract infection.   
In order to find statistical significance in the results, a power analysis using the 
standard deviation of 7.7 ppb that was found in this study indicates that at least thirty-two 
 vii 
eligible participants with NO levels under 30 ppb would be required.  Only 13 such 
participants were examined in this study.  Thus, at least fifty eligible participants would 
be required to find significant results. 
The implication is that even though statistical significance was not achieved, the 
crude mean averages differed between the two groups in participants with NO levels 
under 30 ppb.  This implies that a larger-scale well-designed study is warranted before 
NO is used in clinical settings in the diagnosis and monitoring of patients. 
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INTRODUCTION 
Methods of Studying Airway Disease   
Airway inflammation has been seen in a variety of pulmonary disorders, including 
asthma, chronic obstructive pulmonary disease, and bronchiectasis. Current methods to 
evaluate for disease or inflammation include invasive procedures such as bronchoscopy, 
bronchial biopsy, and bronchoalveolar lavage.  Although it is not invasive, sputum 
induction can involve discomfort to patients.  With this in mind, an alternate method of 
examining airway disease that is non-invasive and produces less discomfort to patients 
has been actively sought by researchers.   
Examination of exhaled breath markers offers a possible alternative method. 
When people exhale, they breathe out warm, humidified air.  This exhaled air contains 
gases, water vapor, and various volatile substances that come from the airways and the 
fluid that lines the airways.  Several of these dissolved substances have been shown to be 
markers of airway disease or inflammation.  Since this exhaled air is easily obtained in a 
non-invasive manner with little discomfort to patients, it shows promise as a method for 
examining the degree of airway disease and/or monitoring patient response to treatment.   
However, measurements of markers in exhaled breath can vary based on the parameters 
used to study them.  For example, the equipment used, the exhalation duration, the 
method of acquiring samples, and the expiratory flow rate can all affect measured values. 
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Nitric Oxide in Exhaled Breath   
One of the exhaled breath markers currently being investigated is nitric oxide 
(NO).  NO has been found to be elevated in various disease states, such as asthma and 
COPD during exacerbations.  Other factors have also been found to affect NO levels.  
(See Table 1)  [11]  For example, a recent study performed by Doctors Robert Haight and 
Robert Gordon comparing nitric oxide levels in old versus young people found increased 
exhaled breath NO levels in older individuals (median = 36.9 ppb) when compared to 
young people (median=18.7 ppb). [17] 
Genetic variation may also play a role in the amount of NO that is exhaled.  An 
understanding of possible sources of genetic variation may be obtained by examining the 
mechanism of NO synthesis.  (See Figures 1 and 2)  “Endogenous NO is primarily 
synthesized from arginine via the enzyme Nitric Oxide Synthase (NOS).” (Kharitanov, 
2001, p. 1694) [8]  
There are 3 different forms of NOS: (1) Type I- Neuronal NOS, (2) Type II- Inducible 
NOS, and (3) Type III- Endothelial NOS.  Types I and III are activated by “small rises in 
intracellular calcium 2o to cell activation.” (Kharitanov, 2001, p. 1694) [8]  Type II “has 
a much greater level of activity…; is independent of calcium concentration …; may be 
induced by inflammatory cytokines, endotoxin, and viral infections; and may show 
increased expression in inflammatory diseases.” (Kharitanov, 2001, p. 1694) [8] 
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Table 1-  Factors That Affect NO Measurements in Healthy Subjects  
INCREASED NO LEVELS DECREASED NO LEVELS 
Pharmacologic  
       Papaverin  NOS inhibitors 
       L-arginine Oxymetazoline 
       Sodium nitroprusside  
       ACE inhibitors (enalapril)  
Physiologic and procedural  
       Arginine ingestion  Repeated spirometry 
        nitrite/nitrate-enriched food Acute & transient after forced exhalation  
 Physical exercise 
 Sputum induction 
 Menstrual cycle 
 Reduced body temperature 
Environmental, Occupational  
        Air pollution (NO, ozone)  Water vapour, CO2, nitrous oxide, heptane  
        Occupational hazards: 100% inspired O2  
            Fluoride, dust  Moderate altitude 
            Rubber latex  
            Ozone, chlorine dioxide   
            Formaldehyde (domestic) exposure  
            Electromagnetic field generated by  
            cellular phone (nasal NO) 
 
Habitual/ Infections  
        URTI Smoking  
 Alcohol ingestion  
Definition of abbreviations:  URTI = upper respiratory tract infection,  
ACE = angiotensin-converting enzyme.  
 
Modified from Kharitanov  SA and Barnes PJ.  Exhaled Markers of Pulmonary Disease. 
Am J Respir Crit Care Med 2001; 163: 1693-1722. [8] 
 
 
  
Figure 1.  Nitric Oxide Synthesis 
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Modified from Kharitanov  SA and Barnes PJ.  Exhaled Markers of Pulmonary Disease. 
Am J Respir Crit Care Med 2001; 163: 1693-1722.  [8] 
 
Figure 2.  Genetic Induction of NOS 
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Modified from Kharitanov  SA and Barnes PJ.  Exhaled Markers of Pulmonary Disease. 
Am J Respir Crit Care Med 2001; 163: 1693-1722. [8] 
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“Genetic polymorphisms of all three isoforms of NOS have been detected.      
Associations have been found between polymorphisms in the NOS1 gene and asthma in 
Caucasian populations…  In patients with mild asthma, there is a significant association 
between the length of the AAT repeat polymorphism in intron 20 of the NOS1 gene and 
exhaled NO levels.” (Kharitanov, 2001, p. 1694) [8]  These findings leave open the 
possibility that genetic variations among different ethnic groups could result in variations 
in baseline NO levels between different ethnic groups. 
It has been assumed that baseline NO levels are the same among different ethnic 
groups.  No prior studies have directly examined whether a difference may exist between 
the different ethnic groups.  This study will examine whether ethnicity could be a factor 
that affects NO levels. 
 
Race and Ethnicity Considerations 
 A race is defined as “any population that differs from other populations of its 
species in the frequency of one or more genes.”  (Bryant, 2004)  It is an arbitrary 
classification based on group.  In comparison, an ethnic group is defined as “a group of 
people who share a similar cultural and regional origin, hold common norms and beliefs, 
and form part of a larger population, interacting with people from other segments of 
society. … Ethnic groups (1) share fundamental cultural and norms that distinguish them 
from other groups, (2) communicate and interact together, reaffirming their ethnic 
identity, and (3) are recognized by members and other groups as distinct.”  (Bryant, 
2004)  [15]   These qualities can create variations among people.  (See Next Section on 
Epidemiologic Considerations) 
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 “In conducting a study, the most valid method of ethnic assessment is self-
identification.” (Bryant, 2004)  [15]  In keeping with this, to assign ethnicity, participants 
of this study will be asked to identify their own ethnicity as a strict criterion.   
 It must be “recognized that historical patterns of migration, intermarriage, and 
distribution of genetic characteristics suggest that there are no pure races.”  (Bryant, 
2004)  [15]  As an example, a person who may be identified as Caucasian may have one 
parent who is Caucasian while another parent is Hispanic.  To gain insight into the 
possibility of mixed ethnicity, participants will also be asked to identify the birthplace of 
their parents and whether they identify the ethnicity of two generations of ancestors 
differently from themselves. 
 
Epidemiologic Considerations 
 A primary consideration in any research study is internal validity.  Internal 
validity is defined as the “extent to which the results of a study are correct for the 
particular group being studied.  Internal validity is a prerequisite for external validity.” 
(Sanchez-Anguiano, 2004)  Once findings have been made through research with care to 
preserve internal validity, a general epidemiologic challenge then becomes to provide 
information that can be applied to populations outside the specific one studied.  [22] 
External validity is defined as “the extent to which the results of a study apply to 
people who were not in the study.”  (Sanchez-Anguiano, 2004)  Many times, in an 
attempt to preserve internal validity, external validity may become compromised.  A 
potential cause of loss of external validity is ethnic differences.  [22] 
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In 1999 and 2005, the American Thoracic Society promulgated recommended 
practices and instruments for obtaining and measuring NO in exhaled breath.  Ethnic 
considerations were not included in these recommendations. [3], [19] 
Ethnic differences have sometimes been found to result in variations in parameter 
measurements based on different factors such as socio-economic status (eg. access to 
health care), environmental factors, and genetic variations.  For instance, pulmonary 
spirometry test results require adjustments in people of African descent in order to 
portray a more accurate clinical representation when measuring their pulmonary function. 
[18]  This suggests the possibility that other pulmonary monitoring parameters may 
require similar adjustments based on ethnic differences.  These adjustments results from 
generalized differences in variables such as those listed above. 
Specifically, in this study, measurement of exhaled breath levels of NO were 
compared between two dominant ethnic groups in American society:  people of non-
Hispanic Caucasian descent and people of African descent.  In performing this study, the 
goal was to begin to provide an examination of the generalizability of exhaled breath 
measurements to various populations. 
 
Research Question  
Are Baseline Measurement Values of Airway Markers of Inflammation In 
Exhaled Breath Generalizable To Different Ethnic Populations?  
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Hypothesis 
To study this, measurements of NO levels in exhaled breath were compared 
between people of Caucasian descent and people of African descent.  The null hypothesis 
was there is no difference in baseline measurements of exhaled breath nitric oxide levels 
between people of Caucasian descent and people of African descent.  The alternate 
hypothesis was that baseline measurements of markers of inflammation in exhaled breath 
varied among different ethnic populations.   
As measurement protocols are developed, such variations, if they exist, should be 
considered to improve accuracy in detecting and monitoring methods of airway disease 
states. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9 
Goals and Objectives 
 The specific objective of the proposed study was to examine whether a difference 
may exist in baseline clinical measurements of exhaled breath NO levels between young, 
healthy men in the two ethnic groups.  The goals were: [1] to begin to provide an 
examination of the generalizability of measurements of exhaled breath markers to various 
populations, which may serve as the basis for a larger and more in-depth study [2] to 
examine whether baseline NO measurements are  appropriately representative of 
individuals from different ethnic backgrounds, [3] to examine whether adjustment factors 
based on ethnicity need to be considered as protocols for measuring markers in exhaled 
breath become advanced for potential use in clinical settings to improve clinical accuracy 
in detection and monitoring of lung diseases. 
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Significance and Utility of Research 
The study was unique since it looked at a hypothesis that had not been previously 
examined in measurements of exhaled breath.  The examination provided insight into the 
possible applicability of measurements of markers in exhaled breath to others groups in 
the general population.  In performing the study, insight was provided to researchers who 
are actively developing methods and parameters to use markers in exhaled breath for the 
detection of pulmonary disease or for monitoring treatment.   
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Materials and Methods 
Overall Study Design   
  In this pilot study, the variable studied was ethnicity and the outcome of 
interest was levels of the marker nitric oxide in exhaled breath.  A cross-sectional design 
was utilized where individual level data was obtained simultaneously.   
  Ten men were compared in each of two ethnic groups.  The men in the 
first group were of African descent, whereas the men in the second group were of 
Caucasian descent.    In this examination, only healthy men aged 18-45 were studied.  
Health was defined as having no history of allergies, asthma, lung diseases, and no 
significant smoking history (defined as less than one-half pack year history with no 
smoking in the past 2 years).  Also, since certain medications have been found to affect 
NO levels, those participants taking any of the medications listed in Table 1 were 
excluded.  Finally, men with severe heart disease or coronary vessel disease were 
excluded as a safety precaution.  
 
Facilities and Equipment 
 The participants were seen at the College of Public Health at the University of 
South Florida in the Breath Laboratory (MHH Room 323).  The records were maintained 
in a secured cabinet in this room.  The key to access the laboratory was distributed by the 
University of South Florida only to authorized personnel (obtained through the College of 
Public Health).  The necessary equipment discussed above that was needed to perform 
this project was available in this room. 
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Participant Recruitment 
Healthy subjects were asked to volunteer for the study through one or two visits at 
the Breath Laboratory at the College of Public Health (MHH Room 323), an air-
conditioned, comfortable room.   They were asked to sit in the same comfortable chair.  
Subjects who expressed a willingness to volunteer were given information about the 
study procedure, the risks, the benefits, and the alternatives to the procedure.  They were 
then asked to demonstrate an understanding of all components discussed.  They were 
encouraged to ask questions at any time.  If they still agreed to proceed, they were asked 
to sign an informed consent.  They were monitored by a physician throughout the visit 
via direct observation.  Because performance of spirometry maneuvers immediately 
before NO measurement affects the NO levels obtained, subjects were given the option of 
presenting for either one or two visits based on their own convenience.  Those subjects 
who chose to present for one visit were asked to perform NO maneuvers before 
spirometry was obtained.  Those subject who completed the study over two visits 
performed the spirometry maneuvers on the first visit and NO maneuvers on the second 
visit.  For one hour prior to the visit where NO levels were obtained, subjects were asked 
not to eat or drink anything and to refrain from strenuous exercise as recommended in 
both the 1999 and 2005 American Thoracic Society (ATS) criteria. [2], [19] 
 
Study Subjects and Restrictions 
Only normal, healthy people aged 18-45 years old who denied any history of 
environmental allergies, asthma, or other lung diseases were invited to participate.  Also, 
they must not have suffered from any recent upper or lower respiratory tract infections. 
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[2], [19]  The study was restricted to men only because there have been reports that the 
level of exhaled breath NO differs between men and women. [16]  Subjects must also 
have no significant smoking history as defined by less than one-half pack-year history of 
smoking, no smoking within the past 2 years, and no significant second-hand smoke 
exposure.  Subjects must refrain from strenuous exercise, food, or drink for one hour 
prior to the test at a minimum per 1999 and 2005 ATS Criteria [2], [19]. 
 
Study Questionnaire and Eligibility 
     During each subject’s first visit, a questionnaire was initially given that asked for 
medical and demographic information.   For those who participated in a second visit, the 
subjects were asked a brief questionnaire on the second visit to ascertain the absence of 
changes during the interim between visits.  During each visit, subjects were also given a 
brief exit questionnaire to help assess any possible adverse effects from the study visit 
itself.  (See Appendices A and B) 
The medical history was elicited to determine “health”, and the demographic 
questionnaire determined age, attained ethnic affiliation, and asked for SES variables.  
(See Appendix A)  In this study, participants were administered a demographic 
questionnaire to assess ethnicity that specifically asked, “How would you classify your 
ethnicity?”  They were also asked where they and their parents were born.  This was done 
to assess migration patterns and differences between subjects within each ethnic group.  
They were asked if they would classify the ethnicity of anyone in two prior generations 
of their ancestors differently from themselves.  Anyone who classified 50% or more of 
their ancestors differently from themselves would be disqualified.  To consider socio-
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economic status differences between the two groups (which may act as a potential 
confounding factor), participants were also asked for their income level and occupation. 
Subjects who fulfilled the criteria of age, ethnicity, and being “healthy” then 
underwent brief physical examination including auscultation.  Those subjects found to be 
healthy after questionnaire, interview, and physical examination were invited to 
participate in the remainder of the study.  To be eligible for the study, all participants 
needed to show normal spirometry.  
Those subjects who chose to participate in two visits performed spirometry on the 
first visit and the NO maneuvers on the second visit.  Alternatively, those subjects who 
chose to participate during a single visit performed the NO maneuvers prior to 
spirometry.  The reason for this is that performance of spirometry maneuvers could affect 
NO levels.  Subjects who chose to participate in two visits were given a brief entry 
questionnaire on the second visit, and auscultation was performed again to ensure 
absence of change in health status during the interval between the first and second visits.   
 
Subject Safety Considerations 
Subject safety was given the utmost consideration in this study.  Subjects were 
told they may discontinue at any time.  The subjects were healthy individuals who agreed 
to participate in the study.  The entire study was non-invasive. 
Furthermore, physical examination and initial medical screening questionnaires 
were reviewed directly by a physician prior to any procedure being performed.  Only 
subjects who had normal physical examination were allowed to continue in the study.  
Spirometry, which is commonly used in clinical practice to assess lung function, was 
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obtained as an eligibility criterion.  To obtain spirometry, subjects blew out through a 
disposable filter  (to prevent infection) using maximum effort after a maximal inhalation.  
Measurement of exhaled breath NO, which is currently still a research tool, involved tidal 
breathing and normal respiration through a disposable plastic filter.  Therefore, it was 
even safer to obtain than spirometric measurements.   
During each visit, subjects were also given a brief exit questionnaire to help 
assess any possible adverse effects from the study visit itself.  For those who participated 
in a second visit, the subjects were asked a brief questionnaire on the second visit to 
ascertain the absence of changes during the interim between visits.   
 Participation in this study did not affect the standard care subjects would receive 
from their personal physicians unless [1] abnormal auscultation or spirometry was found, 
in which case the subject was advised to consult their personal physician, or [2] an 
adverse effect occurred.  In the latter case, most events would only be temporary and 
subside within seconds or minutes after stopping the activity.   Although rare, a subject 
could experience chest pain or other adverse event during spirometry or exhaled breath 
nitric oxide measurement.  In that event, emergency equipment was available at all times 
during the study to assist the individual until appropriate emergency personnel arrives.  
To ensure patient safety, all subjects were directly observed by a physician who was 
ACLS-certified during the entire visit.  The sampling procedure was completely non-
invasive.  Since real-time measurements of exhaled breath were made, no samples were 
kept beyond their immediate measurement. 
 For those individuals who participated in two visits, a questionnaire was 
administered at the start of the second visit to ensure the absence of new symptoms in the 
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interval between visits.  Also, these participants were verbally asked if there had been any 
changes in their health status or medications in the interim. 
 
Physical Examination 
All subjects were assessed for cyanosis and clubbing.  Also, auscultation was 
performed prior to any breathing tests and at the conclusion of each visit.  “Cyanosis is a 
bluish discoloration of the skin resulting from an inadequate amount of oxygen in the 
blood.  Cyanosis occurs when oxygen-depleted blood, which is bluish rather than red, 
circulates through the skin. Cyanosis can be caused by many types of severe lung or heart 
disease or certain malformations that produce low levels of oxygen in the blood. 
Clubbing is an enlargement of the tips of the fingers or toes and a loss of the angle where 
the nails emerge. Finger clubbing occurs when the amount of soft tissue beneath the 
nailbeds increases. The reason this increase occurs is not clear, but clubbing seems to 
occur with some pulmonary disorders (lung cancer, lung abscess, bronchiectasis), but not 
with others (pneumonia, asthma, emphysema). Finger clubbing also occurs with some 
congenital heart diseases or, in some cases, may be inherited and not indicate any 
disease.” (Merck, 2005) [20]  In auscultation, a stethoscope is used to listen to both heart 
sounds and breath sounds.   
Any subject demonstrating cyanosis, clubbing, or abnormal breath sounds was 
immediately disqualified from the study.  Auscultation of the heart was also performed 
for the purposes of subject safety.   
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Acquisition of Spirometry 
Spirometry, which is a common clinical method employed in assessing lung 
function, was performed as part of the entry criteria into the study.  The Koko spirometer 
was used and calibrated using a standard 3-liter syringe to ambient temperature, 
humidity, and barometric pressure at least once a day on days when participants were 
examined.  The spirometer was additionally re-calibrated when at least six hours had 
elapsed since the prior calibration or at the discretion of the examiner. The raw FEV1 and 
FVC measurements obtained for each participant were automatically compared to their 
predicted normal values based on age, ethnicity, weight, height, and non-smoking status 
in determining their percent of predicted values using parameters as set forth by Crapo et. 
al.  
The spirometry parameters examined on each study participant included FEV1, 
FVC, FEV1/FVC ratio, and the flow-volume loop.  At least three spirometric 
measurements were obtained on each subject, with at least one flow-volume loop 
showing good effort.  Proper technique was ensured by evaluating the flow-volume curve 
and continuance of the expiratory maneuver for at least six seconds according to ATS 
criteria.  
A noseclip was placed on the subjects’ noses during the study to prevent nasal 
breathing in order to obtain more accurate spirometry results.   Subjects were asked to 
forcibly exhale for at least six seconds through a disposable single-use filter after 
maximal inspiration, followed by another maximal inhalation. The maneuver was 
demonstrated to them to help achieve consistency.   
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Any subject with abnormal spirometry measurements was notified of this 
information and advised to consult a healthcare provider and disqualified from the study.  
All subjects with an FEV1/FVC ratio greater than 70% of predicted, FEV1 greater than 
80% of predicted, FVC greater than 70% of predicted, and a normal appearing flow-
volume loop were eligible for the study by spirometric criteria.  In those participants who 
did not meet all of these strict criteria, the overall clinical picture, including medical 
history and physical examination were assessed individually to determine study 
eligibility.  When eligibility due to spirometry did not meet these strict criteria, Dr. Stuart 
Brooks (faculty advisor, Board Certified in Pulmonary Medicine) was consulted to 
determine whether the participant would be eligible for the study. 
Adverse effects were unlikey to occur during this phase of the study because 
subjects identified themselves as being in good health, the room was temperature 
controlled, and this phase of the study was brief in duration.  All subject were seated 
during the spirometry.  In the event that adequate trials could not be obtained in the 
seated position as demonstrated by their flow-volume loops, subjects were asked to stand 
and instructed on safety precautions in the event of symptoms.   
Nonetheless, there was the slight possibility of unusual symptoms such as 
lightheadedness, dizziness, chest pains, palpitations, or shortness of breath during the 
spirometry from overexertion in breathing.  As a precaution, subjects were instructed to 
stop, be seated, and notify the physician examiner immediately if they experienced any 
symptoms at any time.   
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Measurement of Exhaled Breath Nitric Oxide 
 The Nitric Oxide Analyzer was calibrated at least on a daily basis on days where 
subjects were being examined.  It was calibrated again when at least 6 hours had elapsed 
since the last calibration.  Additional calibrations occurred at the judgment of the study 
examiner.  NO analysis calibrations were made using zero NO air and air containing 45 
ppm NO.  The flow meter was calibrated with a 3-liter syringe. 
 Subjects were asked to maximally inhale ambient air and then to immediately 
breathe out normally through a single-use disposable filter mouthpiece attached to a flow 
meter at a constant flow rate of 50 milliliters per second as recommended by the ATS. 
The mouthpiece also provided a specific amount of resistance during exhalation to allow 
for velopharyngeal closure to prevent contamination of the exhaled breath NO 
measurements with nasal nitric oxide. (See Figures 3 and 4)  Because exhaled breath NO 
concentrations depended on the rate of airflow, subjects exhaled at a constant airflow rate 
determined by the Nitric Oxide Analyzer (NOA) through biofeedback by real-time 
computer display of their own flow rates.  The NO flow rate was equal to the product of 
NO concentration in the exhaled air multiplied by the airflow rate.  [2], [19]  
 The following ATS recommendations were followed.  ATS recommended an 
exhalation duration of at least six seconds (up to 30 seconds) to obtain at least a 3-second 
plateau of the measured NO level. The plateau was defined as “the first portion of the NO 
versus time profile where [the difference beween the start of the plateau and the end of 
the plateau varied by no more than] 10%.  …Online electronic analysis of NO profiles 
allowed automatic identification of valid NO plateaus according to these criteria.  
…Repeated reproducible exhalations were performed, resulting in three NO plateau 
values that agreed within 10% of the mean value.  …[The ‘average NO level’] was then 
calculated as the mean of these three values.  At least 30 seconds of relaxed tidal 
breathing off the NO measurement circuit elapsed between exhalations to allow the 
subject to rest.”  (ATS, 2005, p. 916) (See Figure 5)  [2]  In certain cases, where 
automatic computer selection chose clearly incorrect plateau levels, the most appropriate 
3-second plateau that met ATS criteria was selected for the calculation of the average NO 
level.   
Figure 3.  Nitric Oxide Flow Rate Versus Time [2], [19] 
 
                           Plateau 1                      Plateau 2                        Plateau 3  
 
 
 
 
 
             Modified from the American Thoracic Society              
 
The mouthpiece apparatus was specially designed with an attached filter during 
inhalation to provide inhalation air at less than 5 ppb NO.  Alternatively- as used in this 
study- ambient air was inhaled, which caused an early peak in real-time NO levels.  In 
this case, plateau levels of NO were equivalent to when NO-free air was inhaled.  
Figure 4.  Flowmeter Design [2], [19] 
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                               Modified From the American Thoracic Society                p. .916 
 
                                                                                Air 
 
 
   
 
                                                                  
                                                                   Place Mouth Here 
Figure 5. Effect of Inhalation of Air Through the Flowmeter Versus Inhalation of 
Ambient Air [2], [19] 
                                               Modified From the    American Thoracic Society, 2005,                         
                                                                                       p.916  
                                           
                  Early Peak 
                                     Gradual Rise                  
                                    
                                  Inhale air with <5ppb NO                Inhale Ambient Air 
 
                                       
 Nitric oxide in exhaled breath was collected in a chamber in the Sievers 280i 
Nitric Oxide Analyzer (Boulder, CO) and measured according to recommended methods 
set forth by the American Thoracic Society in 1999 and 2005.  The machinery contained 
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an ozone generator that produced ozone in the chamber containing the exhaled breath.  
The ozone reacted with the NO within the chamber according to the following 
photochemical reactions:  
NO + O3      NO2
.
  + O2
NO2
.
                    NO2 + hv 
      NO reacted with ozone to form “nitrogen dioxide in an electronically excited state, 
which then emitted light in the red and near-infra-red region of the electromagnetic 
spectrum to return to the more stable state.  This red light generated from the reaction 
was detected by a thermoelectrically cooled, red-sensitive photomultiplier tube within the 
machine.  The Sievers 280i Nitric Oxide Analyzer (Boulder, CO), a high-sensitivity 
detector for measuring NO based on a gas phase chemiluminescent reaction between 
nitric oxide and ozone, was used in measuring NO levels. …  The Nitric Oxide Analyzer 
(NOA) had a sensitivity of 1 ppb NO and measured from 0.1 to 500 ppb nitric oxide 
within a timeframe of 500msec.”  (Sievers, 1995)  [14] 
Since this limb of the study was not a maximal forced exhalation, subjects were 
even less likely to experience symptoms during this phase of the study.  However, 
subjects were be given the same instructions as during the spirometry phase of the study.   
 
Data Collection and Analysis 
To appropriately assess the research question, a large number of eligible subjects 
would have been required to participate. Primarily because of the limited availability of 
subjects who were willing to participate and who met the criteria for entry into this study, 
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it had been undertaken as a pilot study. Therefore, the study was performed with the goal 
of examining at least twenty eligible subjects to provide insight into the question of 
whether a difference may exist between the two ethnic groups.  A power calculation was 
performed which was derived using alpha= 0.05 and power=80% to show the level of 
difference in the means of the two groups that was needed for significance given a 
specific sample size. (See Appendix E)  To do the power calculation, a recent study by 
Kharitanov et al. [9] which reported an average NO level of 17.8 with a standard 
deviation of 6.8 was used for the calculations.   
In any study where there are two groups being compared, the participants are 
ideally randomly assigned to each group.  However, random assignment is not possible 
when two distinct groups are being used such as men versus women or young versus old.  
That was the case in this study, where the two distinct groups were people of Caucasian 
descent versus people of African descent.   
 The mean of each of the two groups in a study sample may be compared using a 
Students’ t-Test, a parametric analysis, when the population studied is normally 
distributed.  When the population is not normally distributed, a non-parametric analysis 
must be used.  In the case where two distinct groups are being compared, non-parametric 
tests include the Wilcoxon Ranked-Sum Test or the Mann-Whitney U Test.  Because the 
overall study set was not normally distributed (probably tri-modal), the Wilcoxon Rank-
Sum Test was used in the statistical analysis of this data.  When those individuals with 
extremely high NO levels were excluded, the remaining data consisted of those subjects 
who were asymptomatic but either did or did not have underlying airway pathology.  
Therefore, a probable bi-modal distribution remained, also requiring calculation using the 
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Wilcoxon Rank-Sum Test.  When all participants with levels over 30 were also excluded, 
the data better resembled a normal distribution for which a Student’s t-Test could be 
used.  However, upon statistical analysis using SAS, the average NO values obtained 
between the two ethnic groups were found to consist of different variances.  Hence, the 
Satterthwaite Test was a more appropriate test to use in this case than the Student’s t-
Test.   (See Appendixces G and H )  
 Statistical calculations were performed by inputting the data into Statistical 
Analysis Software (SAS), which calculated the data automatically.  For this study, SAS 
was utilized to calculate descriptive statistics such as the mean, median, variance, 
standard error of the mean, standard deviation, range, minimum and maximum values, 
skewness, and kurtosis both for each ethnic group and for all of the study subjects 
together.  SAS was also used to calculate inferential statistics:  the Satterthwaite T-Test 
was completed for those subjects with average NO levels below 30.  The Wilcoxon 
Rank-Sum Test was used for statistical analysis of data that was not normally distributed.  
In a crude attempt to assess whether there might be a correlation between SES and NO 
levels, a Pearson-Product Correlation Coefficient was calculated. 
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Study Results 
Exclusions 
In response to recruitment strategies, approximately 15 to 20 men besides those 
who actually participated expressed an interest in being part of the study.  These men 
were excluded on initial contact based on failure to meet all of the entry criteria.  The 
primary reasons included not meeting the age criteria, a history of significant smoking, 
environmental allergies, or asthma.  
Failure in proper communication was demonstrated by five men who presented to 
the lab for testing but did not meet the inclusion criteria.  They were excluded early in the 
informed consent process.  One Caucasian was excluded due to a history of 
environmental allergies.  Another Caucasian male was excluded for current upper 
respiratory tract infection.  He was invited back into the study but chose to withdraw. 
Two men of African descent were excluded due to a significant smoking history.  A fifth 
person was excluded early in the questionnaire process after discovering that he was 
Hispanic.   
No one was excluded due to abnormal auscultation.  All of the men who 
underwent auscultation had normal cardiac examinations with S1 and S2 heart sounds 
with regular rate and rhythm and no murmurs, rubs, or gallops.  Lung exams were clear 
to auscultation bilaterally with no audible wheezes, rales, or rhonchi.  No cyanosis or 
clubbing was noted in the upper extremities. 
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All of the men who completed the spirometry maneuvers had FEV1/FVC ratio 
values above 70%.  After complete participation, two Caucasian men were excluded for  
markedly prolonged expiratory phases on their flow-volume loops despite having FEV1, 
FVC, and FEV1/FVC ratio values that were above the cutoffs for exclusion from the 
study.  Interestingly, both of these men were Caucasian and had the best FEV1/FVC 
ratios between 80-85%, whereas the men who were included had best FEV1/FVC ratios 
between 90-110%.  One of these two men was found to have an average NO level under 
10 parts per billion (ppb), while the other had an NO level between 40-50 ppb.  A third 
Caucasian male who completed the study was subsequently eliminated because he 
reported taking oral steroids.  His NO level was between 10-15 ppb.  One participant of 
African descent who completed the study and denied any history of allergies but reported 
significant runny/ irritated nasal passages compounded with poor spirometry results was 
eliminated due to both spirometry and possible concurrent URI or new-onset of allergies.  
His NO level was 54.5 ppb. 
 
Questionnaire Collection 
 The following tables demonstrate the results of the demographic information that 
was collected during the study.   
TABLE 2.  Number of Subjects in Each Ethnic Group 
Ethnicity Frequency Percent 
African 10 50.00 
Caucasian 10 50.00 
  
Distribution By Age 
Age (yrs) 19 20 21 22 23 24 31 33 34 36 39 40 
African 0 1 0 1 2 3 1 0 1 1 0 0 
 
 E
th
ni
ci
ty
 
Caucasian 1 0 2 1 1 0 0 1 0 1 1 2 
 
Figure 6.  Participant Distribution By Age 
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Table 3.  Sociodemographic Characteristics 
Ethnicity African Caucasian 
Birthplace 
  US  6 10 
  Africa  3 0 
  Jamaica 1 0 
Different Ancestry By Ethnicity? 
No 8 9 
Yes-  Parents Born in Haiti  1 0 
Yes-1/4 Hispanic  0 1 
Yes-Less than 1/4 Various Mixed 1 0 
Current Occupation 
Para-Professional 
(Occupation Code=1) 
1 2 
Student  
(Occupation Code=1) 
6 3 
Professional  
(Occupation Code=2) 
3 5 
Annual Salary 
$0-$20,000 6 4 
$20,000-$50,000  3 4 
$50,000-$100,000 0 1 
Over $100,000  1 1 
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Two variables for socio-economic status (SES) were elicited by the demographic 
questionnaire.  These included current income and current occupation.  Because there 
may be an association between lower SES and asthma, and nitric oxide levels are higher 
in people with asthma, a Pearson-Product Moment Correlation was performed to 
determine if lower SES is correlated with a higher nitric oxide level. [21]   
To do this, the raw data needed to be converted into numerical values to plug into 
the equation for the Pearson-Product Moment Correlation.  Accordingly, the subject 
responses were classified into three groups for occupation:  Student, Para-Professional, or 
Professional.   Students and Para-Professionals each received a score of one point 
whereas professionals received a score of two points.  Salary information, which was 
elicited at $10,000 intervals, was rated at one point for a salary of <$20,000; two points 
for $20,000-$50,000; three points for $50,000-$100,000, and four points for >$100,000.  
The scores from the employment data and the salary data were then multiplied together 
for each individual to arrive at a score representing their socio-economic status.  These 
values were used in the statistical analysis against nitric oxide levels to better visualize 
the descriptive data already obtained. 
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Table 4.  Pearson-Product Correlation Coefficient 
Average NO- 3 Variables:  [1]Salary Code,  [2]Occupation Code, [3] SES Code Product 
Variable N Mean Std Dev Sum Minimum Maximum 
Average 
NO 
20 33.55500 23.47091 671.10000 8.90000 94.40000 
Salary 
Code 
20 1.75000 0.96655 35.00000 1.00000 4.00000 
Occupation 
Code 
20 1.40000 0.50262 28.00000 1.00000 2.00000 
SES Code 
Product 
20 2.80000 2.35305 56.00000 1.00000 8.00000 
Pearson Correlation Coefficients, N = 20  
Prob > |r| under H0: Rho=0 
  SalaryCode OccupationCode SESCodeProduct 
r 
p-value 
-0.05156 
0.8291 
-0.21656 
0.3591 
-0.12463 
0.6006 
 
     When the raw data was considered, a higher NO level was weakly inversely correlated 
with SES.  However, because the p-value was greater than 0.05, the test was not 
statisrically significant.   
 
Medical Information 
     Following are [1] the medical problems that were reported by participants on the 
medical questionnaire, [2]the findings on the physical exam, and [3]the adverse events 
reported by participants upon completion of the study. 
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Table 5.  Medical Information 
Ethnicity African Caucasian 
Prior Respiratory Tract Ailments 
None 10 8 
Reports Bronchitis  >5 years ago 0 1 
Once told he had child-hood asthma but never took 
medications for this; he has never had any symptoms 
0 1 
Current Medications 
None  7 7 
Diabetes medication 1 0 
Glucovance, Enalapril 1 0 
Maxzide, ASA  1 0 
Topical Steroids  0 1 
Tramadol  0 1 
Doxycycline for acne  0 1 
Inhalation Exposures 
Denied 10 7 
Firefighter x 5yrs 0 1 
Roomate smokes, but not in common areas 0 2 
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  Ethnicity 
Other Medical Conditions Reported By Subjects African  Caucasian 
None  6 3 
Acne  0 1 
Atopic Dermatitis  0 1 
Back Pain; Anxiety  0 1 
Diabetes Mellitus; Palpitations from Coffee 1 0 
HTN  1 0 
HTN; Diabetes  1 0 
Irregular Heart Beat  0 1 
Irregular Heart Beat when eating pepperoni  0 1 
Musculoskeletal Complaints  1 0 
Prior subdural hematoma  0 1 
groin hernia age 4 repaired  0 1 
 
 
 
 Ethnicity 
Physical Exam African Caucasian 
WNL 9 9 
Obesity 1 1 
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 Ethnicity 
Adverse Events African  Caucasian 
None  9 9 
None/ got URI that night  1 0 
Raspy Voice and tiredness several hours later; sick the next day 0 1 
 
Spirometry Measurements 
 Of the twenty-four participants on whom spirometry was performed, three 
Caucasians were excluded:  two for having a prolonged expiratory phase on spirometry, 
and one for taking oral steroids.  A fourth male of African descent was excluded for low 
FEV1 and FVC values; he also reporting irritated nasal passages with rhinorrhea.   
The following participants were entered into the study after approval was received 
from Dr. Brooks. One morbidly obese man (>300 pounds) of African descent who had 
low FEV1 and FVC values had a normal flow-volume loop and normal FEV1/FVC ratio.  
His low FEV1 and FVC values were attributed to his increased girth pushing against the 
diaphragm, creating limitations in total lung capacity.  One man of African descent who 
was 79 inches tall had normally appearing flow-volume loops and normal FEV1/FVC 
ratios but low individual FEV1 and FVC readings.  Because spirometry is less accurate at 
the extremes of height, he was included in the study.  Two men with normally appearing 
flow-volume loops, normal FEV1/FVC ratios, and with FEV1 and FVC trials very close 
to 80% were kept in the study after discussion with Dr. Brooks (some degree of operator 
error was involved in each of these two cases).   
 
Exhaled Breath Nitric Oxide Measurements 
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 The data obtained during this study are shown in the figure below: 
Figure 7.  Average NO Level Of Each Subject By Ethnicity 
 
 
 
 
 
 
 
(Note:  Each + Or x Represents One Participant) 
Visualization of the overall results in Figure 7 show that the data obtained was not 
normally distributed for either group.  Inspection of the distribution of values for African 
descent reveals that the data may have contained three or four modes.  The statistical 
analysis of the data is presented in Table 6. 
Table 6.  Statistical Analysis of Average NO Levels for all 20 Participants 
 Overall African Caucasian
N 20 10 10 
Sum Observations 671.1 356.6 314.5 
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Table 6.  Statistical Analysis of Average NO Levels for all 20 Participants 
Median 28.80000 29.20000 27.40000 
Mean 33.555 35.66 31.45 
Lower 95% 
Confidence Level for 
Mean 
22.5702756 14.1217452 20.2160745 
Upper 95% 
Confidence Level for 
Mean 
44.5397244 57.1982548 42.6839255 
 
Std Deviation 23.4709109 30.1084041 15.703945 
Variance 550.883658 906.516 246.613889 
Std Error Mean 5.24825522 9.52111338 4.96602345 
Skewness 1.5873052 1.2238969 2.61550195 
Kurtosis 1.94120303 0.45564928 7.43705885 
 
Range 85.50000 85.50000 52.90000 
Minimum  8.9 8.9 21.0 
Maximum 94.4 94.4 73.9 
  
The above data showed that the mean of the African group was slightly higher 
than the mean of the Caucasian group.  The medians differed by only 1.8 ppb.  The 
African group had a greater variance whereas the Caucasian group showed less variance 
in data with significantly greater kurtosis (peakedness of the curve).   
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Table 7.  Wilcoxon Scores (Rank Sums) for Variable Average NO 
Classified by Variable Ethnicity 
Ethnicity N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
African 10 104.50 105.0 13.223782 10.450 
Caucasian 10 105.50 105.0 13.223782 10.550 
Average scores were used for ties. 
Wilcoxon Two-Sample Test 
Statistic 104.5000 
Normal Approximation 
Z 0.0000 
Two-Sided Pr > |Z| 1.0000 
t Approximation 
Two-Sided Pr > |Z| 1.0000 
Z includes a continuity correction of 0.5. 
 
To show a significant result, the two-tailed z-score calculated by the Wilcoxon-
Rank Sum analysis would need to be at least 1.96 (alpha=0.05%).  Thus non-parametric 
statistical analysis using Wilcoxon-Rank Sum failed to reject the null hypothesis that 
there is no difference between the means of the two ethnic groups. 
When the extreme values above fifty were removed from the data set, the 
following non-normally distributed results were obtained: 
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Table 8.  Statistical Analysis of Average NO Levels When Excluding Extreme Values 
 Overall African Caucasian 
N 17 8 9 
Sum Observations 420.8 180.2 240.6 
Median 25.90000 20.85000 25.90000 
Mean 24.7529412 22.525 26.7333333 
Lower 95% CL for Mean 19.8197848 11.6675971 22.7272157 
Upper 95% CL for Mean 29.6860976 33.3824029 30.7394510 
 
Std Deviation 9.59473278 12.986999 5.21176554 
Variance 92.0588971 168.662143 27.1625 
Std Error Mean 2.32706451 4.59159753 1.73725518 
 
Skewness -0.2552595 0.25915577 0.5170626 
Kurtosis -0.8535283 -2.0829279 -1.1213304 
 
Range 30.70000 30.70000 14.50000 
Minimum 8.9 8.9 21.0 
Maximum 39.6 39.6 35.5 
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Again, the above data showed a significantly different variance between the two 
groups.  This time, however, the mean of the African group is somewhat lower than the 
mean of the Caucasian group.  The medians differed between the two groups by 5.05 ppb. 
Table 9.  Wilcoxon Scores (Rank Sums) for Variable Average NO 
Classified by Variable Ethnicity When Extreme Values Are Excluded 
Ethnicity N Sum of
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
African 8 65.50 72.0 10.385935 8.187500 
Caucasian 9 87.50 81.0 10.385935 9.722222 
Average scores were used for ties. 
 
Wilcoxon Two-Sample Test 
Statistic 65.5000 
Normal Approximation 
  
Z -0.5777 
One-Sided Pr < Z 0.2817 
Two-Sided Pr > |Z| 0.5635 
t Approximation 
  
One-Sided Pr < Z 0.2858 
Two-Sided Pr > |Z| 0.5715 
Z includes a continuity correction 
of 0.5. 
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Non-parametric analysis by the Wilcoxon Rank-Sum test failed to find a 
statistical difference between the means of the two ethnic groups since the two-sided p-
value is greater than 0.05.  It must be kept in mind that this was a pilot study.  Because of 
the small sample size, there was less reliability in the statistical analysis.  A significantly 
larger sample size would have been needed to determine whether or not a truly significant 
difference exists. 
When the data was re-calculated using only those values below 30 in a crude 
attempt to exclude those asymptomatic participants with underlying airway pathology, 
the following data was obtained: 
Table 10.  Statistical Analysis of Average NO Levels When Excluding Levels over 30 ppb 
 Overall African Caucasian 
N 13 6 7 
Sum Observations 274.7 102.2 172.5 
Median 22.50000 12.60000 22.90000 
Mean 21.1307692 17.0333333 24.6428571 
Lower 95% CL for Mean 16.4543913 7.0101150 21.3635183 
Upper 95% CL for Mean 25.8071471 27.0565517 27.9221960 
 
Std Deviation 7.73858133 9.55105579 3.54582249 
Variance 59.885641 91.2226667 12.5728571 
Std Error Mean 2.14629629 3.8992022 1.34019493 
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Table 10.  Statistical Analysis of Average NO Levels When Excluding Levels over 30 ppb 
 
Skewness -0.4877608 0.8640237 0.61145295 
Kurtosis -1.2966622 -1.8466342 -1.6296301 
 
Range 20.80000 20.80000 8.70000 
Minimum 8.9000000 8.9 21.0 
Maximum 29.7000000 29.7 29.7 
 
Table 11.  t-Test of Average NO Levels When Excluding Average NO Values Over 30 
Variable Method Variances DF t Value Pr > |t| 
Average_NO Pooled Equal 11 -1.97 0.0748 
Average_NO Satterthwaite Unequal 6.18 -1.85 0.1131 
 
This time, the means of the two groups differed by 7.6 ppb, whereas the medians differed 
by 10.3 ppb.  Although the two groups still had different variances, the difference in the 
variances between the two ethnic groups was not as great as before.  Again, the statistical 
analysis (Satterthwaite Test for normally distributed data with different variances) failed 
to show a difference between the two means of the ethnic groups as the p-value was 
greater than 0.05.  However, the mean of the African group had dropped even more than 
the decline in the mean of the Caucasian group so that there was an even greater 
difference between the means of the two groups in this small pilot study. 
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     Using the µ and σ data obtained from the normally-distributed participants in this 
study with average NO levels under 30 ppb, the power of the analysis of was calculated 
to be 36.5%. 
 
Table 12.  Calculating The Power Of The Study 
µ1 
N1=6 
µ2 
N2=7 
σ α NCP Critical Value Power 
17.0333 24.6429 7.73858 0.05 3.12391 4.84434 0.36483 
 
Because β = 1 – Power, beta (or the probability of making a type II error) was calculated 
to be equal to 63.5%.   
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Discussion 
Findings 
 To reiterate, the question of interest has been whether a difference exists in the 
average NO levels between two ethnic groups: Caucasians and people of African descent.  
First, information on demographics, socio-economic status, and medical information was 
obtained and described.  The descriptions were summarized as: [1] There was more age 
variability in the Caucasian group when compared to the African group; [2] all 
Caucasians were born in the United States, whereas four of the people in the African 
group were born outside the United States; [3] two men in the African group and one man 
in the Caucasian group report having different ancestry; [4] five Caucasians worked in 
professional occupations, whereas only three of the African men worked in professional 
capacities; [5] most participants reported annual incomes under $50,000.   
Next, in a crude attempt to examine whether a correlation may exist between 
socio-economic status (SES) and average NO levels, individuals were given numerical 
assignments for their stated occupation and income responses, which were then 
multiplied together and used to calculate a Pearson Product Correlation Coefficient (r).  
The analysis resulted in a weakly negative r-value, indicating that there may be a weak 
inverse relationship between SES and NO levels.  However, as expected with the small 
sample size studied, the analysis did not yield a statistically significant result.   
The average NO levels automatically determined by the NOA for each of the participants 
were then plotted to visualize the variability in NOA-determined average NO levels 
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obtained.  (See Figure 7)  Inspection of this figure pointed to a non-normal distribution of 
the data with possible tri-modal distribution.  One mode centered around extreme NOA-
determined average NO values over 60 ppb.  A second mode included individuals with 
normal airways.  A possible third mode could include asymptomatic individuals with 
underlying airway pathology with NO levels between 30-40 ppb.  
Therefore, the “average NO level” data was analyzed in 3 ways:  [1] non-
parametric analysis of the average NO levels for all 20 eligible participants, [2] non-
parametric analysis of the average NO levels excluding participants with extreme NO 
levels over 70 ppb, and [3] parametric analysis of the average NO levels excluding 
participants with average NO levels over 30 ppb.   
In this pilot study, none of the statistical analyses showed significance.   
Nonetheless, when attempts were made to exclude individuals with average NO levels 
over 30 ppb so that the data becomes normally distributed, the mean and median of the 
average NO levels for the African group was 7.6 ppb and 10.3 ppb lower than the mean 
and median for the Caucasian group, respectively.  This indicated the possibility that a 
statistically significant difference could be found in this analysis group when a larger 
sample size is studied.  The power and β of the study for the group of participants with 
NO levels under 30 ppb were calculated to be 36.5% and 63.5%, respectively.  Thus, 
there is a high likelihood of committing a Type II error in this group.  Therefore, in 
participants with NO levels under 30 ppb, the high Type II error rate indicates a high 
probability of missing a true difference between the two means if one really exists.   
In order to find statistical significance in the results, a power analysis was 
performed.  It indicated that at least thirty-two eligible participants with NO levels under 
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30 would be required.  (See appendix E).  At least sixty eligible participants would be 
required to obtain a study sample of sixteen in each group.  The number of willing 
participants needed would be substantial given the strict criteria of the study where 
anyone with a known history of smoking, environmental allergies, asthma, or other lung 
diseases was excluded.  Even then, those participants who were asymptomatic but who 
demonstrated either [1]abnormalities after spirometric testing (for example, prolonged 
expiratory phase), or [2]high NO levels possible indicative of underlying airway 
pathology or an imminent upper respiratory tract infection would also need to be 
excluded. 
Of the three participants who were excluded due to clinically abnormal 
spirometry, two had high NO levels, whereas one had a low NO level.  Thus, the 
presence of abnormal spirometry did not absolutely predict a high NO level in this tiny 
number of excluded participants for spirometry criteria.  As may be expected, one 
participant taking oral steroids had a low NO level.   
 
 Implications 
 The implication gleaned from this study was that statistical significance was not 
achieved due to the small sample size.  However, the crude mean of the average NO 
levels in the normally-distributed male participants (with average NO levels under 30 
ppb) of African descent was found to be 7.6 ppb lower than that for their Caucasian 
counterparts.  This implies that a larger well-designed study may find a statistically 
significant difference and provides a basis for performing a more extensive study 
including both men and women and examining varying ethnic backgrounds (for example, 
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Alaskan native, Pacific islander, etc.) in addition to those studied here prior to the use of 
NO in clinical settings to in the diagnosis or monitoring of patients.  
 
Future Directions 
After investigators of a concurrent capsaicin study mentioned that certain 
asymptomatic participants in their study with extremely high NO levels became ill with 
an upper respiratory tract infection within the next several days of testing, three 
participants with NO levels over sixty were asked to notify the investigator of this study 
if they became ill within the next week.  Two of the three study participants reported the 
onset of an upper respiratory tract infection within the next two days.  The third 
participant had not yet made contact with the investigator.  This generated the hypothesis 
that NO levels may be extremely high in normal individuals up to a few days prior to the 
onset of an upper respiratory tract infection.  Because the current study was not designed 
to investigate this hypothesis, this conclusion would need to be further investigated in a 
properly designed and controlled study to examine whether or not this is the case. 
 Other hypotheses generated by this pilot study include a possible weak inverse 
correlation between SES and average NO level and a possible tri-modal distribution of 
NO levels.  These would also need to be investigated in larger, well-controlled studies 
designed to specifically examine these questions. 
 
Study Limitations 
As a pilot study with only 20 eligible participants, the entire study was of limited 
value.  Nonetheless, the goal here had been to provide a cursory look at the question of 
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whether a difference may exist in baseline nitric oxide levels in members of different 
ethnicities.  
Limitations of the study could effect on its validity.  In this study, calculation of 
the sample size was based on the mean and standard deviation as measured in a prior 
study. [22]  However, it was unknown whether these were the true population values for 
these parameters.  The values measured for mean and standard deviation of average NO 
levels in this study varied significantly from the prior values.  This could affect the 
accuracy of the measurement.   
Errors due to chance may have occurred due to small sampling size.  “The 
stronger the association is in nature, the easier it is to find with a small sample size.  The 
closer the true association is to the null value, the larger sample size you need to find it to 
be statistically significant.”  (Sanchez-Anguiano, 2004, unit 6) [22]  Therefore the results 
of this study showed that it was highly unlikely that there was a strong association 
between exhaled breath NO levels and ethnicity.   
When “the sample is too small, a study is more likely to miss an association, 
increasing the likelihood of a Type II error.”  (Sanchez-Anguiano, 2004, unit 6) [22]  A 
Type II error may have been committed in this study where a weaker association could 
still be present and would not be detected by this study.   
Subjects were asked to participate based on the eligibility criteria of no history of 
allergies, asthma, or lung diseases and no significant smoking history.  Participants with 
NO values over 30 may have had imminent upper respiratory tract infection or 
underlying airway pathology despite being asymptomatic.  With this in mind, the data 
was also calculated when the participants with levels over 30 ppb were excluded.  In 
 47 
doing this, the sample size was reduced even more, further increasing the likelihood of 
error due to chance.  
     Another way the results of the study may have been limited was through bias.  There 
were numerous biases that may have occurred during the study.  An example included 
prevalence-incidence bias, where participants who were “mild or silent cases” were 
missed by the entry criteria and allowed to participate. [22]  Thus, they were 
misclassified.  Other biases may have included observer bias because no blinding 
occurred during the study.  Self-selection bias was present since volunteers were used.  
[22]  Also, a susceptibility bias was present since all subjects were students or workers, 
creating a healthy worker effect.  Thus, the study could not be generalized to the general 
population. [22] 
 Unknown confounders may also have affected the study.  In this study, one 
participant reported taking enalapril on a regular basis.  The investigator had 
inadvertently overlooked that this medication has been found to raise exhaled breath NO 
levels (See Table 1).  However, because the participant’s average NO level was below 10 
ppb, his NO level off the medication would have been even lower than the measured 
value.  In that case, the difference between the means of the two ethnic groups would 
have increased slightly, giving more power to the study.  In essence, the effect of the 
oversight was in the direction closer to the null hypothesis.  Because the power of the 
study was so low, it did not dramatically impact the results of the study.   
Methods of controlling for confounders included restriction, randomization, and 
matching. [22]  Multiple restrictions were used in the study design to attempt to control 
for confounders.  Although randomization is a powerful method of controlling for 
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confounders, it could not be used in this study because two intact groups- Caucasians and 
Africans- were being compared.  Matching would also have been beneficial.  However, it 
would have been “difficult and tedious.  Once a factor had been matched, it could not be 
studied as a risk factor for disease.”  Because the matching would have been by factors of 
socio-economic status, their relationship to NO levels could not have been examined if 
participants were matched based on these factors. (Sanchez-Anguiano, 2004, unit 8) [22]  
[epi unit 8 p. 12]  
 In performing statistical analyses where two distinct groups were compared, three 
underlying assumptions were made:  (1)Assumption of Normality, (2)Assumption of 
Homogeneity of Variance, and (3)Assumption of Independence. [23] 
 Statistical analyses are most robust to violations of the Normality Assumption.  
Still, this was addressed by using a non-parametric Wilcoxon Ranked-Sum Test for 
analysis of data that was not normally distributed. [23] 
 Statistical analyses are moderately robust to the Homogeneity of Variance 
Assumption.  In this study, the two groups had different variances, so this assumption 
was violated.  However, performance of a Satterthwaite analysis attempted to account for 
violations of homogeneity of variance in the group with NO levels under 30 ppb.  
Nonetheless, the Satterthwaite analysis is less reliable for small sample sizes. [23] 
 Statistical analyses are the least robust to the Assumption of Independence, the 
most serious of the violations.  In this study, care was taken not to allow people who were 
genetically related to each other participate in the study.  Everyone participating in the 
study had some association to the University of South Florida (USF).  Two participants, 
one Caucasian male and one African male, were significant others of USF 
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student/employees.  Otherwise, everyone in the study was directly a student or employee 
of USF. 
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Conclusion 
 Given the small sample size (due to difficulty in subject recruitment), the limited 
population that the study could be generalized to, and the various other limitations listed 
above, this pilot study is limited in its value.  Despite this, a raw difference between the 
means and medians of the average NO levels for the two ethnic groups was noted when 
only those participants with average NO levels under 30 ppb were included.  Therefore, 
differences in baseline NO levels between members of different ethnic groups requires 
further study prior to the institution of NO measurements in clinical settings for patient 
care.  
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Appendix A:  Initial Medical and Ethnicity Questionnaires 
 
Subject number:_______ 
Exhaled Breath Study Questionnaire 
Today’s Date _______________________________________ 
Gender:                Male           Female        (circle one) 
What is your date of birth? ______________________ 
How old are you? _____________________________ years old. 
Where were you born? ____________________________________________ 
How would you classify your ethnicity?  
 (Please check one of the following): 
_______Caucasian  
_______African American  
_______Other- Please explain: ________________________________________  
 
Are any of your biological parents or grandparents from a different ethnicity than your 
stated ethnicity above?      YES         NO      (circle one) 
 
Where was your mother born? _____________________________________ 
 
Where was your father born? _______________________________________ 
 56 
 
 
 
What is your current occupation? 
 
________Student 
________Other- Please Specify__________________________________________ 
_____________________________________________________________________ 
 
What is your current annual salary? Please check one of the following: 
(Please note that this information is used solely to further subdivide the subject 
population.  Like all of the other personal information obtained for this study, this 
information will be kept strictly confidential.) 
________$0 to $10,000 per year  ________$60,000 to $70,000 per year 
 
________$10,000 to $20,000 per year     ________$70,000 to $80,000 per year 
 
________$20,000 to $30,000 per year     ________$80,000 to $90,000 per year 
 
________$30,000 to $40,000 per year     ________$90,000 to $100,000 per year 
 
________$40,000 to $50,000 per year     ________More than $100,000 per year 
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________$50,000 to $60,000 per year  
    
Other- please explain: _______________________________________________  
Do you currently have, or have you ever had any of the following conditions listed 
below?  (Please circle YES or NO) 
 
YES NO CHEST PAIN, PALPITATIONS, IRREGULAR HEART    
BEAT, OR HEART DISEASE? 
 
YES NO HIGH BLOOD PRESSURE? 
 
YES NO ASTHMA, BRONCHITIS, EMPHYSEMA, OR OTHER   
LUNG OR BREATHING DISORDERS? 
 
YES  NO DIFFICULT OR HEAVY BREATHING 
 
YES NO  A LARGE AMOUNT OF PHLEGM PRODUCTION 
 
YES NO PREGNANCY? 
 
IF YOU HAVE CIRCLED YES TO ANY OF THE ABOVE QUESTIONS, PLEASE 
EXPLAIN: ___________________________________________________________ 
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___________________________________________________________ 
 
 
Do you have any health problems or past medical history of health problems that you 
have seen a physician for? Please list them below. 
 
                     1._________________________________________________________ 
                      
                     2. ________________________________________________________ 
                         
                     3. ________________________________________________________ 
 
                     4. ________________________________________________________ 
 
                      5.________________________________________________________ 
 
Are you taking any medications?  If so please list them below. (Including over the 
counter medications) 
                     1. ________________________________________________________ 
                 
                     2. ________________________________________________________ 
                         
                     3. ________________________________________________________ 
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                     4. ________________________________________________________ 
 
 
                     5. ________________________________________________________ 
                     
           6. ________________________________________________________ 
 
                     7. ________________________________________________________ 
 
At this point in time, to what degree do you note the following symptoms?  
(a) Phlegm production: 
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT          ___VERY 
MUCH  
 
(b) Runny or irritated nose or nasal passages: 
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT  ___VERY MUCH  
 
(c) Throat irritation or burning sensation: 
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT  ___VERY MUCH  
 
(d) Sensation of a “weight” or tightness of the chest:  
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT  ___VERY MUCH  
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(e) Feeling of chest pain, burning, or tightness: 
___NONE  ___VERY LITTLE  ___MODERATE AMOUNT  ___VERY MUCH  
 
If you have ever smoked, please answer the following: 
 
      How many packs per day did you smoke? ________________________ 
 
      For how many years did you smoke? ____________________________ 
 
     When did you stop smoking? __________________________________ 
 
 
On what date were you last ill? _____________________________________ 
 
 
 
 What illness did you have? ________________________________________ 
 
Please circle YES or NO to the following questions: 
 
Are you exposed to second hand smoke at home or at work?  
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                  YES      or      NO         
 
Were you or are you exposed to any gases, dusts, or fumes at your job? 
                        YES      or       NO 
 
           If so, please explain:   ____________________________________________ 
 
_____________________________________________________________________ 
 
Do you ever wheeze or become short of breath?     
         YES      or      NO         
 
 
This is the end of this questionnaire.  Thank you for taking the time to fill it out.  
Special thanks to Dr. Gwyn Crump for allowing the use of his questionnaire in this study.  
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Second Visit Initial Study Questionaire 
 
SUBJECT NUMBER:  ________________________________________  
 
Are you currently experiencing any of the following symptoms?  
(Please Circle YES or NO) 
 
(1) Difficult or heavy breathing?  YES    NO 
 
(2) Feeling of chest pain, tightness, pressure, or burning?   
YES      NO  
 
(3) Any new symptoms that were not present during your first visit      here?     YES   NO 
 
(4) Any other unusual symptoms?     YES   NO 
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Appendix B:  Exit Questionnaire 
 
Post-Study Questionaire  
 
SUBJECT NUMBER:  ________________________________________  
 
Are you currently experiencing any of the following symptoms?  
(Please Circle YES or NO) 
 
(1) Difficult or heavy breathing?  YES    NO 
 
(2) Feeling of chest pain, tightness, pressure, or burning?   
YES      NO  
 
(3) Any new symptoms that were not present when you arrived    
       here today?     YES   NO 
 
(4) Any other unusual symptoms?     YES   NO 
 
Special Thanks To Dr. Gwyn Crump for developing the majority of this questionnaire! 
  
 
Appendix C:  Recruitment Flyer 
 You Are Invited To Participate!  
 
 What?  
 A $20.00 total honorarium will be given to each volunteer who completes the 
study for valuable time spent participating.  
 This study only makes measurements of the normal air breathed out by subjects. 
The tests will measure lung function & a constituent of the air people breathe out called 
Nitric Oxide. 
 This research study is non-invasive, meaning you will not be given any drugs or 
subjected to invasive procedures such as needlesticks as part of the study. 
  Who? 
 Healthy men with normal lungs who have never smoked and have no allergies. 
 Candidates must be 18-45 yrs old & either Caucasian or people of African 
descent. 
  Why? 
 The study is designed to examine whether a certain marker found in the air we 
normally breathe out is different in normal young, healthy people of African descent as 
compared to Caucasians.  Your participation in this study may help to determine whether 
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adjustments should be made in measurement of this marker in people of African descent 
to help more accurately portray when disease is or is not occurring.  Hopefully, the 
results will benefit science. 
  When? 
The study will take about two hours to complete.  You may choose to participate either: 
During two visits which will last for approximately one hour each, or 
During a single visit which will last approximately two hours.  
  Where? 
 USF College of Public Health - Call (813) 391-9385 
  If you may be interested or  have any questions, please call (813) 391-9385 or e-
mail us at spatel5@hsc.usf.edu
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Appendix D:  Adult Informed Consent Form 
 
Informed Consent for an Adult 
University of South Florida 
Information for People Being Asked to Take Part in Research Studies 
IRB Study # 103323 
 
Doctors and researchers at University of South Florida (USF) study diseases and other 
health problems people have.  We try to find better ways to help treat these health 
problems. To do this, we need the help of people who agree to take part in a research 
study.  
Title of Research Study:  Exhaled Breath Nitric Oxide:  Is There a Baseline Difference 
Due to Ethnicity? 
Persons in Charge of Study:  Sunita I. Patel, MD; Stuart M. Brooks, MD 
Where the study will be done:  University of South Florida, College of Public Health, 
MHH Room 323 
Who is paying for the study:  Sunshine Education Research Center 
Should you take part in this study? 
This form tells you about this research study.  You can decide if you want to take part in 
it.   You do not have to take part.  Reading this form should help you decide if you want 
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to take part in the study.  If, at any time, you have any questions feel free to ask the 
person explaining this study to you. 
Before you decide: 
Read this form. 
Talk about this study with the study doctor or the person explaining the study.  You can 
have someone with you when you talk about the study. 
Find out what the study is about. 
This form explains: 
The purpose of this research study. 
What will happen during this study and what you will need to do. 
The potential benefits of being in this study, if any. 
The risks of having problems because you are in this study. 
The answers to any questions you might have. 
You can ask questions: 
You may have questions this form does not answer.  If you do, ask the study doctor as 
you go along. 
You don’t have to guess at things you don’t understand. Ask the people doing the study 
to explain things in a way you can understand. 
After you read this form, you can: 
Take your time to think about the information that has been provided to you.  
Have a friend or family member read the form. 
Talk it over with your regular doctor. 
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It’s up to you: 
If you choose to be in the study, then you can sign the form.   
If you do not want to take part in this study, you do not sign the form.   
Why is this research being done? 
The purpose of this study is to find out if there is a difference between Africans and 
Caucasians in the amount of a certain substance in the air we breathe out called nitric 
oxide.  This research could eventually lead to development of more accurate baseline 
measurements of this and other markers in exhaled breath in Africans or individuals of 
other ethnicities, such as Asians, Alaskan Natives, Hispanics, etc.  
The air we breathe out is currently the subject of intense research.  There are certain 
substances in this air whose levels are affected by specific diseases associated with the 
lungs.  In this study, one of these substances in the breath is called nitric oxide.  Your 
breath will be measured by having you breath out into a single-use, clean, disposable tube 
that has never been used before.  Each tube is discarded after you have used it.  Two 
ethnic groups are being examined in this study because, in the past, ethnic differences 
have sometimes been found to affect certain clinical measurements.   
Why are you being asked to take part? 
You must be a healthy person of a certain ethnicity and age group to be eligible for the 
study.  You will not be eligible if you have had any recent upper or lower respiratory tract 
diseases, heart or blood vessel disease, or hernias.  You may have had a recent respiratory 
tract disease if you have had any recent fever, chills, coughing, shortness of breath or 
difficulty breathing, nasal congestion, runny nose, sinus congestion or headache, colored 
phlegm or (green, yellow, brown, black, or red), crackling or whistling sounds heard 
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when you breathe, diagnosis by a doctor of nose/sinus/lung infections, or recent treatment 
with antibiotics for any of these symptoms.  You may not be eligible if you have any 
other diseases or health problems.  We are asking you to take part in this study because 
you are a healthy young Caucasian or African adult between 18-45 year of age.  We want 
to find out if there is a difference in the exhaled breath measurements between healthy 
Caucasians and Africans.   
Your regular medical treatment will not actually be part of the research study. In fact you 
will not be eligible for the study if you suffer from any significant heart or lung disease or 
other significant medical problems.   
How long will you be asked to stay in the study? 
You will be asked to spend a total of about 2 hours in this study.   
You may choose to complete this study on two one-hour visits at least twelve hours apart.  
On each visit, this hour is used to complete the screening questionnaires, perform a 
limited non-invasive physical examination, and for breathing tests.   
Alternatively, you may choose to complete the study in a single 2-hour visit.  If you 
select this option, the same procedures will be performed, but in a different order. 
 How often will you need to come for study visits? 
A study visit is one you have with the study doctor.  This visit is different than the visits 
you make with your regular doctor.  You will need to come for up to two study visits in 
all.   
At these study visits, the doctor will obtain a questionnaire both before and after testing, 
perform a brief physical exam consisting primarily of listening to your heart and lungs 
using a stethoscope, and perform the breathing tests.   
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How many other people will take part? 
About 50 people will take part in this study at USF.    
Will the medical treatment you get from your regular doctor change if you take part in 
this study? 
The kind of treatment you now get from your regular doctor will not change because you 
take part in this study.  You will keep seeing your regular doctor.  Your regular doctor 
will give you the same kind of treatment you would get anyway, whether you take part in 
the study or not. 
If you need it, you can  
Use other medicines prescribed that will help your disease.   
Get any surgery you need. 
You will need to talk to the study doctor about any surgery you have planned. 
Talk to your regular doctor about the treatments you may need. 
If you have an emergency, you can get emergency care. 
Other procedures can be used for measuring airway disease.  These include 
bronchoalveolar lavage/ bronchial biopsy (which are invasive), or sputum induction 
(which can be less comfortable).  These procedures, which can be ordered by your 
regular doctor if needed clinically, will not be performed here.   
What other choices do you have if you decide not to take part in this study? 
An alternative of being part of this research study is to not participate in this study. There 
will be no changes in your life. You will continue with your regular life style and are 
instructed to visit your personal physician for any respiratory or non-respiratory problem 
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you were being followed for before the study. The same is true if you decide to 
participate in the study. 
If you decide you do not want to take part in this study that is okay.  There are other 
choices such as chest X-ray/CT, bronchoalveolar lavage, biopsy, or sputum induction that 
are considered to be the current standard of clinical care for diagnosing airway disease. 
How do you get started? 
You must be of a certain ethnicity and age group to be eligible for the study. You must 
also be healthy to participate in this study.  Volunteers must be between ages 18 and 45. 
If you decide to participate in this study, you will be required to review this informed 
consent, discuss the study and your possible participation with the study doctor and 
decide whether you are interested in participating.  If you decide to take part in this study, 
you will need to sign this consent form.  This informed consent must be signed before 
any study-related test or procedure can be done. After signing this informed consent, 
screening tests will be completed to help determine if you meet the requirements to be in 
the study. You will be asked to fill out questionnaires, undergo a limited physical 
examination and perform a limited breathing test called spirometry.   
Screening tests are tests done to see if you are able to be in the study.  In order to qualify, 
you must record a normal health history.  You must record a negative respiratory 
questionnaire response to treatment for any lung, nasal, or sinus diseases. You must not 
be suffering from any major cardiovascular condition. 
There are different tests performed. These tests are considered non-invasive and do not 
involve drawing blood or inserting tubes into your throat or nose.  
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We will do these screening tests: 
1.   Questionnaires: You will be asked to fill out questionnaires about your health,  
ethnicity, and socioeconomic status.  They will include medical questionnaires.  A post-
study symptom questionnaire will also be given at the end of each visit. 
2.     Physical Examination: Listening with a stethoscope to your chest and abdomen. 
3.   Spirometry: This is a common, frequently used and accepted medical test for 
evaluating how your lungs are working.  Abnormal spirometry may indicate that you 
have a lung disease such as emphysema, chronic bronchititis, asthma, and other diseases. 
The test involves taking in a deep breath and then blowing out into a tube as hard and as 
fast as you can. The spirometer measures the amount and speed with which you forcibly 
exhale your deep breath.  You will be notified if your spirometry test results are abnormal 
and advised to see your personal physician. 
The test results will come back right away.  At the end of each of these screening tests, 
you and the research team will decide whether or not you should be in the study.  
What will you need to do to get ready for this study? 
You will need to refrain from strenuous physical exercise (such as running, jogging, 
working out with exercise equipment, participating in sports, or doing any heavy physical 
labor), eating, or drinking for a minimum of one hour prior to the visit. 
You must be of a certain ethnicity and age group to be eligible for the study. You must 
also be healthy to participate in this study.  Volunteers must be between ages 18 and 45. 
If you decide to participate in this study, you will be required to review this informed 
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consent, discuss the study and your possible participation with the study doctor and 
decide whether you are interested in participating.  This informed consent must be signed 
before any study-related test or procedure can be done. After signing this informed 
consent, medical tests will be completed to help determine if you meet the requirements 
to be in the study. You will be asked to fill out a questionnaire, undergo a physical 
examination and perform a breathing test.  In order to qualify, you must record a negative 
respiratory questionnaire response to treatment for respiratory diseases, including asthma, 
emphysema, chronic bronchitis, sinusitis and interstitial lung disease. You must not be 
suffering from any major cardiovascular condition. 
There are different tests performed. These tests are considered non-invasive and do not 
involve drawing blood or inserting tubes into your throat or nose.  
What will happen during this study?  
Only normal, healthy, non-smoking subjects without second hand smoke exposure or 
history of heart/lung/other diseases ages 18-45 years old will be invited to participate.  
You will be asked to verify that they have not had any signs of recent upper or lower 
respiratory tract infections.  This would include any recent  fever, chills, coughing, 
shortness of breath or difficulty breathing, nasal congestion, runny nose, sinus congestion 
or headache, colored phlegm or (green, yellow, brown, black, or red), crackling or 
whistling sounds heard when you breathe, diagnosis by a doctor of nose/sinus/lung 
infections, or recent treatment with antibiotics for any of these symptoms.  At a minimum 
of 1 hour prior to each visit, subjects will be instructed not to eat or drink or participate in 
strenuous exercise. 
If you decide to participate in two one-hour visits:  
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On the first visit, you will be asked to volunteer for the study.   If you volunteer, you will 
be given information about the study procedure, the risks, the benefits, and the 
alternatives to the procedure.  Then you will be asked if you have any questions and 
demonstrate an understanding of everything discussed.  If you still agree to proceed, you 
will be asked to sign an informed consent.   You will be taken to the Breath Laboratory at 
the College of Public Health (MHH Room 323)- an air-conditioned, comfortable room, 
and sit in a comfortable chair.   
You will be asked to complete a symptom questionnaire, medical history form to 
determine “health”, and a short questionnaire to determine age and ethnicity.  Those who 
fulfill the criteria of age, ethnicity, and being “healthy” will be asked to participate in the 
study.  You will then undergo brief physical examination including auscultation.  You 
will be directly watched by a physician throughout the remainder of the study via direct 
observation.   
Limited spirometry (including FEV1, FVC, and FEV1/FVC ratio), which is part of a 
common method done in hospitals and clinics to check lung function, will be done to help 
verify that your breathing is normal.  A loose-fitting device resembling a clothespin will 
be placed on the nose during the study to obtain better spirometry results.  You will be 
asked to forcibly exhale into a disposable single-use tube using maximum effort after 
maximal inhalation.  Anyone who has abnormal spirometry measurements will be 
notified of this information and advised to consult a healthcare provider and disqualified 
for the remainder of the study.   
Adverse effects are extremely uncommon during this phase of the study because subjects 
are young/ healthy individuals, the room is temperature controlled, you will be seated 
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during the spirometry, and this phase of the study is brief in duration.  Nonetheless, there 
is the remote possibility of unusual symptoms such as lightheadedness, dizziness, chest 
pains, palpitations, or shortness of breath during the spirometry from overexertion in 
breathing.  As a precaution, you will be instructed to notify the physician examiner 
immediately if you experience any symptoms at any time.  Following this, auscultation 
will be performed again and you will be given another brief symptom questionnaire to 
make sure you have no adverse effects from spirometry. 
On the second visit, which will occur at least 12 hours after the first visit, you will be 
asked if there have been any changes in your health status since the first visit.  You will 
be given the same safety and autonomy instructions as during the spirometry phase of the 
study.  After physical exam (primarily auscultation), you will be asked to rinse out your 
mouth with tap water to prevent contamination of the sample.   
Next, the actual study exhaled breath testing, which is strictly part of the research, will be 
performed to measure the amount of nitric oxide in the breath.  You will be asked to 
breathe out through a disposable plastic mouthpiece connected to a filter at a constant rate 
of flow after a maximal inspiration (which is where you take as deep a breath in as you 
can to fill your lungs with as much air as possible).  Following this, the investigator will 
again perform a brief physical examination using a stethoscope to listen to your heart and 
lungs and you will be given another brief symptom questionnaire to make sure you have 
no adverse effects from the second visit.  
Some study visits may be longer or shorter than one hour depending primarily on both 
the equipment and subject variability in breathing.  
At your last visit, you will be asked to verify the absence of symptoms prior to leaving. 
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If you decide to participate in a single two-hour visit:  
The same procedures described above for two one-hour visits will be performed.  
However, The study exhaled breath testing, which is strictly part of the research, will be 
completed prior to spirometry.  Also, examination with a stethoscope will be performed 
at the beginning of the visit, after the study exhaled breath testing, and at the end of the 
visit.   
We will study two groups of people: 
People in one group will be Caucasian.  People in the other group will be of African 
background. 
Sometimes people of different ethnicities may exhale different levels of markers that we 
can measure in the breath.  We want to examine whether levels of the marker nitric oxide 
are different between Caucasians and Africans at baseline. 
Right now, we do not know for sure if the measurement of nitric oxide in your breath will 
accurately measure lung disease.  We are doing this study to find out if the measurement 
of nitric oxide in your breath is different based on your ethnicity.   
If the measurement is not accurate, you may still have airway or lung disease that is 
undetected by the study.  You should consult your own physician regardless of the study 
results if you have any concerns or experience any symptoms at any time. 
During this study, here is what you will need to do: 
Subjects will be instructed to refrain from eating, drinking, or strenuous exercise for at 
least one hour prior to the visit. 
Will you be paid for taking part in this study? 
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We will pay you for the time you volunteer while being in this study.  You will receive a 
total of twenty dollars for completion of the study.   
If you select to participate in two one-hour visits, you will receive five dollars for 
completing the first visit and fifteen dollars for completing the second visit. 
If you select to participate in a single two-hour visit, you will receive twenty dollars if 
you complete the entire study. 
What will it cost you to take part in this study? 
The study will pay the costs of limited physical exam (primarily auscultation), limited 
spirometry, and the experimental nitric oxide measurement. 
You will not have to pay the fees for tests in this study that are not a part of regular 
medical care for your disease/condition.   
Those subjects that do not have a parking permit for on-campus parking will have to pay 
for any parking costs incurred as required from the University of South Florida by taking 
part in this study.   
You will have to pay for your regular care or any other costs.  Your insurance plan should 
cover your regular costs.  Your insurance plan will not have to pay for study costs of 
limited physical exam, limited spirometry, or exhaled breath nitric oxide measurement. 
What are the potential benefits if you take part in this study? 
We don’t know if you will get any health benefits by taking part in this study.  We do not 
know if nitric oxide measurement will help in diagnosing airway or lung diseases.  That 
is why we are doing this study.   This research study should help us learn whether nitric 
oxide measurement will help in diagnosing airway or lung diseases.   
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Since a medical questionnaire, limited physical exam, and limited spirometry will be 
performed, overt abnormalities detected by your examiner will be relayed to you.  You 
will be instructed to consult your regular doctor regarding these findings. 
No matter what, we will learn more about exhaled breath nitric oxide levels in Africans 
compared to Caucasians.  We will learn more about whether differences do or do not 
exist.  What we learn may help others who are actively studying nitric oxide levels in 
exhaled breath for potential use in clinical settings. 
What are the risks if you take part in this study? 
The treatment might not help. 
Right now we do not know for sure if the measurements are consistent.  Because of this, 
you will have to consult your regular physician if you are experiencing any shortness of 
breath, other symptoms, or have any concerns about disease status.  If you do, your 
condition/disease may get worse. 
There may be adverse effects. 
You may have problems because of the procedure used in this study.  These problems are 
called adverse effects.  Some adverse effects are just a bother.  Others could harm you.  
There may be some adverse effects that we don’t know about yet. 
Here are the known adverse effects that could happen with this study: 
This study poses minimal risk to you.  Spirometry is a standard, routine physical test 
commonly performed in hospitals and some clinics.  It is a noninvasive and relatively 
safe procedure and involves the requirement for maximal expiratory effort.  Thus, there is 
a minimal risk that you may breathe too hard during the forced expiratory maneuvers.  
This could result in: [1]“hyperventilation”, where too much carbon dioxide is blown off 
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in a short period of time or [2]excessive physical exertion.  Immediate effects you could 
experience from “hyperventilation” or excessive physical exertion may include 
lightheadedness, dizziness, chest pain or pressure, rapid heart beat, or shortness of breath.   
These usually resolve upon discontinuing the procedure.  You are instructed to 
immediately notify the examiner if any symptoms result.  A determination by the 
examiner of whether or not to continue with the study will be made on an individual 
basis. At any time, both you and the examiner have the right to stop the study for any 
reason.  If you were to continue despite these symptoms, loss of consciousness or 
cardiopulmonary arrest could result in rare cases, requiring emergency treatment and/or 
hospitalization.  In such rare cases, permanent effects could result. 
Patients with history of any type of hernia are excluded from the study since they could 
potentially aggravate the hernia using maximal expiratory effort. 
The procedure for collecting exhaled breath nitric oxide is very similar to the procedure 
for spirometry, except that the subject is asked to breathe out at a slow regular rate 
instead of the forced maximal exhalation required in spirometry.  Thus, it poses even less 
risk and discomfort to the subject than spirometry. 
Private medical information will be collected during the study to find out your health 
status.  The health information is being collected only as a guide for participation in the 
study.  The questionnaires used in the study must remain confidential.  To maintain your 
confidentiality, the questionnaires and recorded data from the study will be kept in a 
locked file cabinet.  Access to the material will only be made to the investigators of the 
study.  Also, as an additional measure to ensure confidentiality, each person will be given 
a subject number.  This will be the only identifier listed on the questionnaires to link the 
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confidential information to the subject.  The master list linking subjects to their subject 
numbers will also be kept in the locked cabinet, but separately.  
During the study, the safety of the normal subjects will be maintained by: [1] the 
presence of a physician at all times of testing; [2] careful direct physician observation and 
monitoring of subjects during testing, and [3] instruction of subjects to immediately 
discontinue the exercise and notify the physician should they experience any shortness of 
breath, chest pain or pressure, dizziness, lightheadedness, or other unusual symptoms.  
No medications will be given during the study, but emergency equipment will be present, 
and a physician will be in attendance for every study patient.  
      
If you have any of these or any other problems, notify your study doctor immediately.  If 
these side effects bother or worry you, or if you have other problems, call your study 
doctor at (813) 974-7545.  If you have an emergency, go to the closest emergency room 
or clinic for treatment. 
You may also have problems from the medical treatment you would usually get.   
We may need to stop your treatment.  If we find that the breathing tests are causing 
adverse events, we will stop the procedure.  Early stopping criteria include: 
 1. For individual subjects: 
The following criteria will be used to discontinue participation in the study: 
[1] You wish to withdraw from the study. 
[2] You do not meet the criteria for inclusion into the study. 
[3] You demonstrate abnormalities on spirometry, physical examination, or monitoring 
through the study. 
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[4] You complain of chest pain or pressure, palpitations, or tachypnea. 
[5] If you experience other symptoms, they will be assessed by a doctor and assisted in 
any way needed.  A decision will be made whether you may continue to participate in the 
study provided that your safety has not been compromised.  In this case, the decision to 
continue would require mutual willingness on your part to continue the study. 
[6] The safety of the researcher is compromised (for example, a hostile subject). 
 2. For the study: 
The study will be terminated if thehealth or safety of the volunteers or examiners 
becomes jeopardized by an unforeseen event. 
 
Is there any risk to your unborn children if you take part in this study? 
Pregnant women will not be allowed to participate in the study.  There are no adverse 
effects for men with partners of childbearing age. 
If you are a woman 
You are excluded from the study if you are or may be pregnant or breastfeeding due to 
the study protocol, since the study results may be affected.  If you are pregnant and you 
inadvertently take part in this study, the risk of adverse effects is still minimal, especially 
if you are in the first trimester of pregnancy.  Nonetheless, it could be that your unborn 
children may have problems now or in the future. 
Tell one of the study doctors right away if: 
You are pregnant. 
You get pregnant. 
You are breastfeeding. 
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If you are a woman 
If you take part in this study, you must use a good birth control method, like oral 
contraceptives or condoms. 
What if you get sick or hurt while you are in the study?  
If you need emergency care:  
Go to your nearest hospital or emergency room right away.  Call 911 for help.   It is 
important that you tell the doctors at the hospital or emergency room that you are 
participating in a research study.  If possible, take a copy of this consent form with you 
when you go.  You should know that the USF does not provide emergency care.   
Call the study doctors as soon as you can.  They will need to know that you are hurt or ill.  
Call Dr. Sunita Patel, MD or Dr. Stuart Brooks, MD at (813) 974-7545. 
If it is NOT an emergency, and you get hurt or sick while you are taking part in this 
study:  
Go to your regular doctor.  It is important that you tell your regular doctor that you are 
participating in a research study.  If possible, take a copy of this consent form with you 
when you go.   
The USF Medical Clinics may not be able to give the kind of help you need. You may 
need to get help somewhere else. 
If you are harmed while taking part in the study: 
The state of Florida enjoys what is called "sovereign immunity."  This means that you 
usually cannot sue the state of Florida.  However, the state has waived sovereign 
immunity (agreed to be sued) in certain situations.  One of those situations is if a state 
employee, such as your study doctor or other USF employee, is negligent in doing his or 
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her job in a way that harms you during the study.  The money that you might recover 
from the state of Florida is limited in amount. 
 
You can also call the USF Self Insurance Programs (SIP) at 1-813-974-8008 if you think: 
You were harmed because you took part in this study. 
Someone from the study did something wrong that caused you harm, or didn’t do 
something they should have done. 
Ask the SIP to look into what happened.   
What will we do to keep your study records private? 
Federal law says we must keep your study records private.  Private medical information 
will be collected during the study to ascertain the health status of the subjects.  The health 
information is being collected only as a parameter for participation in the study.  It is 
obtained after discussion with the subjects that the study is only open to healthy subjects.  
Thus, the questionnaires in the study must remain confidential.  We will keep the records 
of this study private by keeping them in a locked file cabinet.  Access to the material will 
only be made to the investigators of the study.  Also, as an additional measure to ensure 
confidentiality, each subject will be given a subject number.  This will be the only 
identifier listed on the questionnaires to link the confidential information to the subject.  
The master list linking subjects to their subject numbers will also be kept in the locked 
cabinet, but separately.  
However, certain people may need to see your study records.  By law, anyone who looks 
at your records must keep them completely confidential.  The only people who will be 
allowed to see these records are: 
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The medical staff who are taking care of you. 
Certain government and university people who need to know more about the study.  For 
example, individuals who provide oversight on this study may need to look at your 
records.  These include the University of South Florida Institutional Review Board (IRB) 
and the staff that work for the IRB.  Other individuals who work for USF that provide 
other kinds of oversight may also need to look at your records.  Other individuals who 
may look at your records include:  the Florida Department of Health, people from the 
Food and Drug Administration (FDA), the United States Department of Health and 
Human Services, and the United States Department of Labor.  This is done to make sure 
that we are doing the study in the right way.  They also need to make sure that we are 
protecting your rights and your safety.) 
People at the company who paid for this study at the Sunshine Education and Research 
Center (funded by the National Institute of Occupational Safety and Health, a 
governmental department under the United States Department of Labor may look at the 
study records and pertinent portions of your medical records to make sure the study is 
done in the right way.  
We may publish what we find out from this study.  If we do, we will not let anyone know 
your name.  We will not publish anything else that would let people know who you are.   
What happens if you decide not to take part in this study? 
You should only take part in this study if you want to take part.   
If you decide not to take part: 
You will not be in trouble or lose any rights you normally have.  
You will still have the same health care benefits. 
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You can still get your regular treatments from your regular doctor. 
What if you join the study and decide you want to stop later on? 
You can decide after signing this informed consent document that you no longer want to 
take part in this study.  If you decide you want to stop taking part in the study, tell the 
study staff as soon as you can.  If you decide to stop, you can continue getting care from 
your regular doctor. 
Are there reasons we might take you out of the study later on? 
Even if you want to stay in the study, there may be reasons we will need to take you out 
of it.   You may be taken out of this study if: 
We find out it is not safe for you to stay in the study.  For example, your health may 
worsen.  Or we may find out that the device used to measure spirometry or exhaled 
breath nitric oxide might harm you.  Then you may be taken out of the study. 
You are not coming for your study visits when scheduled. 
You can get the answers to your questions. 
If you have any questions about this study, call Dr. Sunita Patel at (813) 974-7545. 
If you have questions about your rights as a person who is taking part in a study, call the 
Division of Research Compliance of the University of South Florida at (813) 974-9343. 
 
Signatures for Consent to Take Part in this Research Study 
It is up to you to decide whether you want to take part in this study.  If you want to take 
part, please read the statements below and sign the form if the statements are true. 
I freely give my consent to take part in this study.  I understand that this I am agreeing to 
take part in research.  I have received a copy of this consent form to take with me. 
I choose to participate in the study as: (Please select only one option) 
      Two visits which will last approximately one hour per visit. 
      A single visit which will last approximately two hours. 
 
____________________________________________     ___________ 
Signature of Person Taking Part in Study   Date 
 
____________________________________________   
Printed Name of Person Taking Part in Study 
 
____________________________________________     ___________ 
Signature of Witness Date 
 
____________________________________________   
Printed Name of Witness 
Statement of Person Obtaining Informed Consent 
I have carefully explained to the person taking part in the study what he or she can 
expect. 
I hereby certify that when this person signs this form, to the best of my knowledge, he or 
she understands: 
What the study is about. 
What needs to be done. 
What the potential benefits might be.  
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What the known risks might be.   
I also certify that he or she does not have any problems that could make it hard to 
understand what it means to take part in this study. This person speaks the language that 
was used to explain this study. 
This person reads well enough to understand this form or, if not, this person is able to 
hear and understand when the form is read to him or her. 
This person does not have a medical problem that makes it hard to understand what is 
being explained and can, therefore, give informed consent.   
This person is not taking drugs that make it hard to understand what is being explained 
and can, therefore, give informed consent.   
 
____________________________________________     ___________ 
Signature of Person Obtaining Informed Consent  Date 
__________________________________________________ 
Printed Name of Person Obtaining Informed Consent 
 
____________________________________________     ___________ 
Signature of Witness Date 
____________________________________________   
Printed Name of Witness] 
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Appendix E:  Power Analysis 
Power Calculation:   Using power= 80% and α = 0.05, the following formula was 
derived: 
 
  a = 2.8 √ 2σ2/n  .    where 
a = level of difference required for significance,  
σ = standard deviation of the population,  
n = sample size.  
 
sigma 6.8 7.7 10
1 26.927 30.49 39.598 
2 19.040 21.56 28.000 
3 15.546 17.604 22.862 
4 13.463 15.245 19.799 
5 12.042 13.636 17.709 
6 10.993 12.448 16.166 
7 10.177 11.524 14.967 
8 9.520 10.78 14.000 
9 8.976 10.163 13.199 
10 8.515 9.642 12.522 
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11 8.119 9.193 11.939 
12 7.773 8.802 11.431 
13 7.468 8.457 10.983 
14 7.196 8.149 10.583 
15 6.952 7.873 10.224 
16 6.732 7.623 9.899 
17 6.531 7.395 9.604 
18 6.347 7.187 9.333 
19 6.177 6.995 9.084 
20 6.021 6.818 8.854 
30 4.916 5.567 7.230 
40 4.257 4.821 6.261 
50 3.808 4.312 5.600 
60 3.476 3.936 5.112 
70 3.218 3.644 4.733 
80 3.010 3.409 4.427 
90 2.838 3.214 4.174 
100 2.693 3.049 3.960 
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Appendix F:  SAS Program Used 
*Read an Excel spreadsheet and import it into SAS as filename=hospital when correcting 
for the confounders; 
PROC IMPORT DATAFILE = 'F:\thesis_excel_data_fbile.xls' OUT = hospital; 
PROC PRINT DATA = hospital; 
TITLE 'RawData'; 
RUN; 
*Create a new SAS file=sorted that sorts the data by Ethnicity; 
PROC SORT DATA = hospital OUT = sorted; 
 BY Ethnicity Average_NO; 
 PROC PRINT DATA = sorted; 
RUN;  
*Create a new SAS file=ranges that sorts the data by Average_NO; 
PROC SORT DATA = hospital OUT = ranges; 
 BY Average_NO; 
 PROC PRINT DATA = ranges; 
RUN;  
*Initiate export of the data to HTML file; 
ODS HTML BODY = "F:\sorted"; 
   CONTENTS = "F:\sorted"; 
   PAGE = "F:\sorted"; 
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   FRAME = "F:\sorted"; 
*Creates a report of total number of subjects in Each Ethnic Group; 
PROC FREQ DATA = sorted; 
 TABLES Ethnicity; 
 TITLE 'Number of Subjects in Each Ethnic Group'; 
RUN; 
*Creates a report of Age by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS Age Ethnicity; 
 TABLE Age, Ethnicity; 
 TITLE 'Age By Ethnicity'; 
RUN; 
*Creates a report of birthplace by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS Birthplace Ethnicity; 
 TABLE Birthplace, Ethnicity; 
 TITLE 'Birthplace By Ethnicity'; 
RUN; 
*Creates a report of AncestralDifference by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS AncestralDifference Ethnicity; 
 TABLE AncestralDifference, Ethnicity; 
 TITLE 'Different Ancestry By Ethnicity'; 
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RUN; 
*Creates a report of CurrentOccupation by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS CurrentOccupation Ethnicity; 
 TABLE CurrentOccupation, Ethnicity; 
 TITLE 'Current Occupation By Ethnicity'; 
RUN; 
*Creates a report of AnnualSalary by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS AnnualSalary Ethnicity; 
 TABLE AnnualSalary, Ethnicity; 
 TITLE 'Annual Salary By Ethnicity'; 
RUN; 
*Creates a report of RespiratoryTractConditions by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS RespiratoryTractConditions Ethnicity; 
 TABLE RespiratoryTractConditions, Ethnicity; 
 TITLE 'Respiratory Tract Conditions By Ethnicity'; 
RUN; 
*Creates a report of Inhalation Exposures by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS InhalationExposures Ethnicity; 
 TABLE InhalationExposures, Ethnicity; 
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 TITLE 'Inhalation Exposures By Ethnicity'; 
RUN; 
*Creates a report of OtherMedicalConditions by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS OtherMedicalConditions Ethnicity; 
 TABLE OtherMedicalConditions, Ethnicity; 
 TITLE 'OtherMedicalConditions By Ethnicity'; 
RUN; 
*Creates a report of CurrentMedications by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS CurrentMedications Ethnicity; 
 TABLE CurrentMedications, Ethnicity; 
 TITLE 'CurrentMedications By Ethnicity'; 
RUN; 
*Creates a report of PhysicalExam by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS PhysicalExam Ethnicity; 
 TABLE PhysicalExam, Ethnicity; 
 TITLE 'Physical Exam By Ethnicity'; 
RUN; 
*Creates a report of AdverseEvents by ethnicity; 
PROC TABULATE DATA = sorted; 
 CLASS AdverseEvents Ethnicity; 
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 TABLE AdverseEvents, Ethnicity; 
 TITLE 'Adverse Events By Ethnicity'; 
RUN; 
*Create a statistical summary of Average_NO values overall ADDED ALPHA; 
PROC UNIVARIATE DATA = sorted mu0=33.5 ALPHA= .05; 
 VAR Average_NO; 
 TITLE 'Statistical Summary Overall'; 
RUN; 
*Create a summary of NO descriptive statistics overall REMOVED DUPLICATES and 
ADDED CONFIDENCE LIMITS; 
PROC MEANS DATA = sorted MIN MAX ALPHA=.05 CLM; 
 VAR Average_NO; 
 TITLE 'Means*Summary Overall'; 
RUN; 
*Create a statistical summary of Average_NO values by ethnicity ADDED ALPHA; 
PROC UNIVARIATE DATA = sorted mu0=33.5 ALPHA= .05; 
 VAR Average_NO; 
 BY Ethnicity; 
 TITLE 'Statistical Summary By Ethnicity'; 
RUN; 
*Create a summary of NO descriptive statistics REMOVED DUPLICATES and ADDED 
CONFIDENCE LIMITS; 
PROC MEANS DATA = sorted MIN MAX ALPHA=.05 CLM; 
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 VAR Average_NO; 
 BY Ethnicity; 
 TITLE 'Means*Summary By Ethnicity'; 
RUN; 
*Create a GRAPH of Average_NO versus ethnicity ADDED ALPHA; 
PROC PLOT DATA = sorted; 
 PLOT Average_NO * Ethnicity; 
 TITLE 'Statistical Summary'; 
RUN; 
*Correlate SES data to NO levels; 
PROC CORR DATA = sorted; 
 VAR SalaryCode OccupationCode SESCodeProduct; 
      WITH Average_NO; 
 TITLE 'Correlate SES Data to NO Levels'; 
RUN; 
*Perform a student’s T-Test on the normally distributed values under 30; 
proc ttest data=sorted; 
var average_no; 
class ethnicity; 
RUN; 
*Calculate Wilcoxon Ranked-Sum; 
proc npar1way data = sorted wilcoxon; 
  class ethnicity; 
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  var Average_NO; 
run; 
 
data twosample; 
Mu1=17.0333333; Mu2=24.6428571; StDev=7.73858133; 
N1=6; N2=7; Alpha=0.05; 
NCP = (Mu2-Mu1)**2/((StDev**2)* 
(1/N1 + 1/N2)); 
CriticalValue = FINV(1-Alpha, 1, 
N1+N2-2, 0); 
Power = SDF(’F’, CriticalValue, 1, N1+N2-2, NCP); 
proc print data=twosample; 
run; 
*Closes the HTML function; 
ODS HTML CLOSE; 
 
 
 
 
 
 
 
 
